Sequenom to Sell Down Syndrome Test 2 Years After Pullback

Sequenom Inc. said its prenatal test for Down syndrome will be available in 20 U.S. cities today, two years after an earlier effort was delayed because employees mishandled research data.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.